APA (7th ed.) Citation

J, A., YA, E., L, R., & MA, H. (2022). Proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with diffuse systemic sclerosis: A marker of disease activity and severe disease manifestations with potential therapeutic implementations. Archives of rheumatology, 38(2), 249. https://doi.org/10.46497/ArchRheumatol.2023.9638

Chicago Style (17th ed.) Citation

J, Artin, Elsabagh YA, Rashed L, and Hussein MA. "Proprotein Convertase Subtilisin/kexin 9 (PCSK9) in Patients with Diffuse Systemic Sclerosis: A Marker of Disease Activity and Severe Disease Manifestations with Potential Therapeutic Implementations." Archives of Rheumatology 38, no. 2 (2022): 249. https://doi.org/10.46497/ArchRheumatol.2023.9638.

MLA (9th ed.) Citation

J, Artin, et al. "Proprotein Convertase Subtilisin/kexin 9 (PCSK9) in Patients with Diffuse Systemic Sclerosis: A Marker of Disease Activity and Severe Disease Manifestations with Potential Therapeutic Implementations." Archives of Rheumatology, vol. 38, no. 2, 2022, p. 249, https://doi.org/10.46497/ArchRheumatol.2023.9638.